Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma;Meta-análisis sobre el rendimiento diagnóstico de la tomografía por emisión de positrones con 18F-FDG en el carcinoma de células renales

Revista Espanola de Medicina Nuclear

Volumn 26, Issue 1, 2007, Pages 19-29

  Martinez De Llano S R ^a   Delgado Bolton, R C ^b,c   Jimenez Vicioso A ^b   Perez Castejon M J ^b   Carreras Delgado, J L ^c   Ramos, E ^a   Rotger, A ^a   Jimenez F ^a   Alonso, J C ^a   Bittini, A ^a   Dominguez P ^a   Almoguera, M ^a   Perez Vazquez J M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Instituto PET Focuscan   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Renal cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMAGING; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; META ANALYSIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 33847748524     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13097378     Document Type: Article

References (24)

1. Marston Linehan W, Bates SE, Yang JC. Cancers of the Genitourinary System: Section 1: Cancer of the Kidney. En: De Vita Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005. p. 1139-67.
2. Tavani A, La Vecchia C. Epidemiology of renal-cell carcinoma. J Nephrol. 1997;10:93-106.
3. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, editors. AJCC Cancer Staging manual. 6th ed. New York: Springer; 2002.
4. Moss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987;14:36.
5. 18F-FDG-PET. Madrid: Agencia de Evaluación de Tecnologías Sanitarias. Instituto de Salud Carlos III; 2002.
6. Centers for Medicare and Medicaid Services. (Fecha de acceso 20 de diciembre 2004). Disponible en: www.cms.hhs.gov/manuals/103_cov_determ/ ncd103cl_Part4.pdf.
7. Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol. 1991;146:1470-4.
8. Kang DE, White RL Jr, Zuger JH, Sasser HC, Teilang CM. Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806-9.
9. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [(18) FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30:1236-45.
10. Flynn K, Adams E, Anderson D. Positron emission tomography: descriptive analysis of experience with PET in VA and systematic reviews (FDG PET as a diagnostic test for cancer and Alzheimer's disease). Management Decision and Research Center (MRDC) Technology Assessment Program (MTA 94-001-02), October 1996.
11. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88-94.
12. Thornbury JR, Kido DK, Mushlin AI, Phelps CE, Mooney C, Fryback DG. Increasing the scientific quality of clinical efficacy studies of clinical studies of magnetic resonance imaging. Investigative Radiology. 1991;26:829-35.
13. Ruiz Hernández G, Delgado-Bolton RC, Fernández Pérez C, Lapeña-Gutiérrez L, Carreras Delgado JL. Meta-análisis de la eficacia diagnóstica de la PET-FDG en pacientes con sospecha de recurrencia por cáncer de ovario. Rev Esp Med Nucl. 2005;24:161-73.
14. 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003;44:1301-14.
15. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293-316.
16. Mijnhout GS, Hooft L, Tulder M, Deville W, Teule GJ, Hoekstra O. How to perform a comprehensive search for FDG-PET literature? Eur J Nucl Med. 2000;27:91-7.
17. Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D. Improving the quality of reports of meta-analysis of randomized controlled trials: the QUORUM statement. Quality of Reporting of Meta-analysis. Lancet. 1999;354:1896-900.
18. Gisbert JP, Bonfill X. ¿Como realizar, evaluar y utilizar revisiones sistemáticas y meta-análisis? Gastroenterol Hepatol. 2004;27:129-49.
19. Majhail NS, Urbain JL, Albani JM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995-4000.
20. Ramdave S, Thomas GW, Berlangieri SU. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2001;166:825-30.
21. Goldberg MA, Mayo-Smith WW, Papanicolau N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol. 1997;52:510-5.
22. Jadvar H, Kherbache HM, Pinski JK. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003;60:395-400.
23. Safaei A, Figlin R, Hoh CK. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol. 2002;57:56-62.
24. Grégoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: Is there a Tower of Babel bias? J Clin Epidemiol. 1995;48:159-63.